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Nuclear receptor NR2F6 inhibition potentiates
responses to PD-L1/PD-1 cancer immune
checkpoint blockade
Victoria Klepsch 1, Natascha Hermann-Kleiter1, Patricia Do-Dinh1, Bojana Jakic1, Anne Offermann2,
Mirjana Efremova3, Sieghart Sopper 4, Dietmar Rieder3, Anne Krogsdam3, Gabriele Gamerith4, Sven Perner2,
Alexandar Tzankov 5, Zlatko Trajanoski 4, Dominik Wolf4,6 & Gottfried Baier 1
Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer
samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic
ablation of Nr2f6, particularly in combination with established cancer immune checkpoint
blockade, efficiently delays tumor progression and improves survival in experimental mouse
models. The target genes deregulated in intratumoral T lymphocytes upon genetic ablation of
Nr2f6 alone or together with PD-L1 blockade reveal multiple advantageous transcriptional
alterations. Acute Nr2f6 silencing in both mouse and human T cells induces hyper-
responsiveness that establishes a non-redundant T-cell-inhibitory function of NR2F6. NR2F6
protein expression in T-cell-infiltrating human NSCLC is upregulated in 54% of the cases (n
= 303) and significantly correlates with PD-1 and CTLA-4 expression. Our data define NR2F6
as an intracellular immune checkpoint that suppresses adaptive anti-cancer immune
responses and set the stage for clinical validation of targeting NR2F6 for next-generation
immuno-oncological regimens.
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Dysfunction of appropriate immune responses is a crucialevent in cancer development and progression. Thedevelopment of immuno-oncological therapies is likely to
revolutionize cancer care in the future1–10. Particularly, anti-
bodies blocking cell surface immune system inhibitory receptors,
such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and
programmed cell death-1 and its ligand-1 (PD-1)/(PD-L1), referred
to as “immune checkpoints”, have been approved for many cancer
types including melanoma, non-small cell lung cancer (NSCLC),
urothelial cancer and Hodgkin’s Lymphoma11–17. In addition,
adoptive T-cell transfer and cancer vaccines are also providing more
encouraging results, especially when combined with antibodies
antagonizing the above-mentioned immune checkpoints18–20. Even
though encouraging, the percentage of patients profiting from these
therapies is limited, highlighting the need to further improve
immune-activating therapy concepts. Particularly, the identification
and validation of alternative and potentially additive or even
synergistic immune checkpoint candidates is envisioned to improve
immunotherapies and extend their benefits to a larger number of
cancer patients.
Pursuing this vision, we considered it reasonable to explore the
checkpoints that might be located inside the immune cells, besides
those present on the cell surface, and might be suitable targets for
future cancer drugs. Following this line of argumentation, we
demonstrated the crucial role of the lymphocyte-intrinsic orphan
nuclear receptor NR2F6 (Nuclear receptor subfamily 2, group F,
member 6; alias Ear2 and COUP-TFIII) as an intracellular check-
point candidate fine-tuning adaptive immunity. NR2F6 induced an
anti-inflammatory signal in the T-cell compartment. Consistent
with this observation, Nr2f6-deficient mice spontaneously devel-
oped a late-onset autoimmune-type phenotype and were hyper-
susceptible to induction of experimental neuroinflammation21.
Mechanistically, NR2F6 acts as an essential signaling intermediate
and sets the threshold of T-cell effector functions by acting as a
transcriptional repressor that directly antagonizes the DNA acces-
sibility of activation-induced NFAT/AP-1 transcription factors at
key cytokine gene loci such as Il2 and Ifng22.
Recently, it has been shown that the genetic elimination of
NR2F6 improves intratumoral CD4+ and CD8+ T-cell infiltra-
tion as well as effector functions at the tumor site in transplan-
table B16-OVA mouse tumor model systems23. Importantly,
these tumor growth effects depend primarily on NR2F6 function
in both CD4+ and CD8+ effector (but not regulatory) T-cell
subsets. However, a rigorous assessment of the physiological
relevance of NR2F6 function in clinically relevant mouse cancer
model systems as well as in human T-cell biology has not yet been
carried out. Employing methylcholanthrene (MCA)-induced
sarcoma as well as MC38 colon adenocarcinoma model systems
and human NR2F6 knockdown T-cell cultures as well as ana-
lyzing tumor-infiltrating lymphocytes (TIL) in human NSCLC
biopsy samples, we here provide strong pre-clinical evidence that
upregulation of NR2F6 at the tumor site renders effector T cells
incapable of mounting sufficient anti-cancer immune response.
Most importantly, combined genetic ablation of NR2F6 with the
established PD-L1 checkpoint blockade is strongly synergistic.
Furthermore, these clear anti-tumor immune responses in the
Nr2f6−/− therapy groups were not accompanied by any signs of
immune-related adverse events (irAE). Thus, our study sets the
stage for future clinical validation of NR2F6 targeting as a
mechanistically independent and potentially synergistic option to
improve the efficacy of immuno-oncology therapies.
Results
Loss of NR2F6 function augments tumor rejection. Nr2f6-
deficient mice were significantly more resistant to development of
MCA-induced sarcoma than wild-type mice (Fig. 1a) and
exhibited reduced tumor growth during challenge with a primary
sarcoma cell line derived from MCA-treated wild-type mice
(Fig. 1b, c). Intratumoral immune cells in the MCA sarcoma
model contained more abundant CD45+ and CD3+ lymphocytes
in Nr2f6−/− versus wild-type Nr2f6+/+ mice (Fig. 1d, e). The
CD3+ pool of TILs from these tumors showed no preference for
the CD4+ or the CD8+ population (Supplementary Fig. 1H, I). In
addition to the spontaneous MCA tumor model, we challenged
wild-type and Nr2f6-deficient mice subcutaneously with the
transplantable colon adenocarcinoma cell line MC38 and
observed decreased tumor outgrowth (Fig. 1f) and a significant
survival benefit (Fig. 1g) in Nr2f6−/− mice. These results firmly
establish that the genetic ablation of Nr2f6 improves immune-
mediated tumor control, finally resulting in a striking benefit in
these advanced mouse models relevant to clinical cancer.
Of note, the augmented anti-tumor immune response in
Nr2f6−/− mice were linked to a markedly higher PD-1 and PD-L1
expression on CD8+ and CD4+ T-cell subsets in vitro when
compared to wild-type animals (Supplementary Fig. 1A–D),
suggesting a potential resistance mechanism via upregulation of
T-cell exhaustion markers. Interestingly, PD-L1 expression was
increased not only in CD45+ leukocytes (Supplementary Fig. 1F)
but also in CD45− cells (Supplementary Fig. 1E) when comparing
wild-type and Nr2f6-deficient B16-OVA tumor-bearing mice on
d14 after tumor challenge, suggesting that loss of NR2F6 in
T cells overcomes even high expression of these well-known
immune-suppressive checkpoint receptors. In order to exclude
“emergency” granulo-monocytopoesis as a main or contributing
factor to the enhanced tumor rejection in Nr2f6-deficient mice,
hematopoietic stem cells, myeloid progenitor cells and myeloid
cells within the bone marrow were investigated following tumor
induction. In line with this observation also no differences
between wild-type and Nr2f6-deficient myeloid cells such as
neutrophils (CD45+Ly-6G+CD11b+), eosinophils (CD45+Ly-6G
−SSChi) or monocytes (CD45+Ly-6G−CD11b+), within latter
population divided into CD115+Ly-6Clo and CD115+Ly-6Chi
cells, were observed (Supplementary Fig. 1J, K). Together, in
Nr2f6-deficient tumor-bearing mice, no significant differences in
the frequency or number in either of these innate immune cell
populations could be detected on day 14.
Genetic ablation of NR2F6 augments PD-L1 blockade therapy.
Based on these findings, we next studied immunotherapy regi-
mens targeting different checkpoints concomitantly. Challenging
Nr2f6+/+ and Nr2f6−/− mice with a high tumor load of 5×105
B16-OVA or 7.5×105 MC38 colon carcinoma cells, all wild-type
mice receiving control IgG injections rapidly developed tumors
and had to be sacrificed due to ethical reasons at the latest by d21
post injection. In line with our previous results, tumor outgrowth
in IgG2b-treated control group of Nr2f6−/− mice was sig-
nificantly delayed even with this high tumor load and was well
comparable to the benefit of blocking the interaction of PD-1
with its ligand PD-L1 in vivo in wild-type mice (Fig. 2a−d). As a
remarkable result, however, a clear synergistic benefit of PD-L1
blocking in Nr2f6−/− mice could be observed. This combination
therapy was clearly more potent than targeting a single immune
checkpoint and even led to rejection of tumors upon challenge
with such very high tumor cell numbers of both the B16-OVA
(Fig. 2a, b) as well as the MC38 mouse tumor cell line (Fig. 2c, d
and Supplementary Fig. 2A−E). Of note, immune infiltration
analyses in vivo of the Nr2f6 knockout group in those high-dose
tumors models, in principle, recapitulated the situation of the low
dose model (see Supplementary Fig. 3A, B). This provides strong
preclinical evidence that NR2F6 and PD-1 signaling may act
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together as “threshold regulators” in host-protective tumor
immunity. Despite the dramatically improved clinical outcome in
Nr2f6−/− tumor-bearing mice subjected to PD-L1 blocking
(combinatorial NR2F6/PD-L1 inhibition group) when directly
compared to wild-type mice under mono-therapy, no exacerbated
signs of irAE were observed during a follow-up period of
3 months (Table 1). We did not see any significant differences in
immune cell infiltrates, colon length or weight gain after anti-PD-
L1 treatment in Nr2f6-deficient mice, when compared to wild-
type mice similarly treated (unpaired Student’s t-test). To eval-
uate the contribution of CD4+ and CD8+ T cells to the observed
decreased tumor outgrowth, we challenged Nr2f6−/−
subcutaneously with 1×105 B16-OVA melanoma cells and treated
them with CD4+ and CD8+ depleting antibodies. We could show
a significantly enhanced tumor outgrowth in Nr2f6−/− mice
treated with a combination of CD4+ and CD8+ depleting anti-
bodies when compared to the IgG2b-treated Nr2f6−/− control
group (Supplementary Fig. 2F).
Taken together, genetic NR2F6 ablation acts as a “sensitizer”
that allows improved therapeutic activity of the clinically
approved PD-1/PD-L1 axis blockade in experimental mouse
tumor model systems. Hence, releasing the inhibition imposed by
NR2F6 appears to be a suitable strategy to vastly enhance efficacy
of cancer immunotherapy.
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Fig. 1 Nr2f6−/− mice reject transplantable chemically and induced subcutaneous tumors. a Wild-type (n= 15) and Nr2f6-deficient (n= 18) mice were
injected with 200 µg MCA and monitored over 300 days; the percentage of sarcoma-free mice is shown (p= 0.0007, ANOVA). From the MCA-induced
pool of mice, several cell lines were generated. Tumor growth (b) and survival (c) of one representative wild-type tumor cell line re-injected into wild-type
and Nr2f6−/− mice (n= 6) with 1×106 cells/mouse is shown (p<0.0001, b ANOVA, c log-rank test). d Significantly enhanced absolute cell numbers of
tumor-infiltrating CD45+ leukocytes (p= 0.018, unpaired t-test, n= 5) and CD3+ T cells (p= 0.031, unpaired t-test, n= 5) per 0.1 g of tumor tissue in
wild-type (black) and Nr2f6−/− (green) mice spontaneously developing chemically induced (MCA) sarcomas. e Representative dot blots of tumor-
infiltrating CD3+ T cells from Nr2f6+/+ or Nr2f6−/− mice are depicted. Numbers adjacent to outlined areas indicate the percentage of positive cells relative
to parental CD45+ gate. Summary of 2−3 independent experiments is shown and data are expressed as the mean ± SEM. f The kinetics of tumor cell
growth in Nr2f6+/+ (n= 12, black) and Nr2f6−/− (n= 6, green) mice subcutaneously injected with 5×104 MC38 colon carcinoma cells (p < 0.0001,
ANOVA) as well as g significant survival benefit in Nr2f6−/− by a Kaplan-Meier curve are shown, and statistically analyzed by a log rank test (p= 0.0007,
log-rank test)
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Coinhibition of NR2F6 and PD-1 alters gene signatures of TIL.
It has been shown that NR2F6-mediated transcriptional repres-
sion of key cytokine gene loci such as Ifng and Il2 contributes to
an immune suppressed state of tumor antigen-specific effector
T cells at the tumor site23. However, the specific target genes of
NR2F6 on a systemic level remained undefined. It was thus
mandatory to further investigate the network of critical target
genes suppressed and/or activated by Nr2f6 gene induction within
the tumor microenvironment (TME).
In order to determine the transcriptional signatures of the
observed superior cancer immune response associated with
genetic Nr2f6 inhibition, alone and particularly in combination
with the established PD-1/PD-L1 axis blocking, we next examined
the network of critical target genes in CD3+ TILs, employing a
stratified CD45+/CD3+ sorting strategy. As expected, tumor
growth in Nr2f6−/− mice was significantly reduced (Supplemen-
tary Fig. 3A) and tumors exhibited significantly increased
numbers of tumor-infiltrating CD45+CD3+ T cells when
compared to wild-type animals, calculated at the level of total
numbers on a tumor size basis (Supplementary Fig. 3B). RNA
sequencing (RNAseq) analysis of TILs derived from wild-type
and Nr2f6−/− tumor-bearing mice collected at d14 after B16-
OVA tumor cell injection clearly demonstrated that the NR2F6-
and PD-1-mediated immune-suppressive pathways are mechan-
istically distinct (Fig. 3a). Further, the control IgG2b-treated or
PD-L1 mono-therapy groups were distinctly different with respect
to gene expression programs (Supplementary Fig. 3D–F).
Simultaneous genetic ablation of NR2F6 and PD-1/PD-L1
interaction blockade significantly affected multiple gene ontology
terms analyzed by ClueGO (Supplementary Table 1–6). Detailed
analysis of differentially expressed genes with respect to over-
represented GO terms showed upregulation of several immune
processes related to adaptive immune activation responses such
as cell-mediated cytotoxicity, IFNγ signaling, T-cell receptor
signaling and TNF signaling pathways (Fig. 3b, c and Supple-
mentary Table 1–6). Processes related to nucleosome assembly or
RNA transport were downregulated (Fig. 3d). Furthermore, gene
set enrichment analysis showed enrichment of genes associated
with T cells in general and Th1 cells in particular (Fig. 3e) in
Nr2f6−/− tumor-bearing mice treated with the anti-PD-L1.
Several gene signatures known to be favorable for T-cell-
mediated tumor rejection (Fig. 3f) were also found to be
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Fig. 2 Gene ablation of NR2F6 acts as “sensitizer” for the established immune checkpoint blockade in mouse tumor models in vivo. a Tumor growth curve
(p<0.0001, ANOVA, n= 9) and b Kaplan−Meier survival curve (p<0.0001, log-rank test, n= 9) of Nr2f6+/+ and Nr2f6−/− mice that received the high
dose of 5×105 B16-OVA tumor cells subcutaneously and were treated either with “mono-therapies” of genetic Nr2f6 inhibition (green, IgG2b) or PD-L1
blockade in wild-type mice (dashed black, employing the established Ab10F.9G2) or treated with a “combination therapy” (red) (n= 8). c Tumor growth
(p < 0.0001, ANOVA) and d Kaplan−Meier survival curves (p= 0.0031, log-rank test) of Nr2f6+/+ and Nr2f6−/− mice that received the high dose of
7.5×105 MC38 tumor cells subcutaneously and were treated either with “mono-therapies” of genetic Nr2f6 inhibition (green, IgG2b isotype control, n= 7)
or PD-L1 blockade in wild-type mice (dashed black, n= 10, the latter employing the established protocol with neutralizing Ab10F.9G2) or with a
“combination therapy” (red, n= 12) (wild-type IgG2b control group, black, n= 5). Results shown are derived from at least two independent experiments.
Error bars represent the mean ± SEM
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deregulated in CD3+ TILs from tumor-bearing Nr2f6-deficient
mice additionally treated with anti-PD-L1. In order to proof the
in silico analysis of a deregulated lymphocyte activation and
metabolic function, we investigated the extracellular acidification
mirroring the pH of sorted CD3+ T cells in vitro and were able to
observe a significant higher acidification in the media of Nr2f6-
deficient T cells reasoning a higher metabolic rate of lymphocytes
(Supplementary Fig. 3C).
Taken together, targeting the NR2F6 pathway is a mechan-
istically independent option in cancer treatment regimens and
identifies a candidate role of the orphan nuclear receptor NR2F6
in governing effector T-cell function relevant for cancer cell
rejection.
Heterozygous Nr2f6+/− mice similarly demonstrate the benefit.
To evaluate the effect of partial versus complete Nr2f6-deficiency
on tumor growth suppression, we injected wild-type Nr2f6+/+,
heterozygous Nr2f6+/− and knockout Nr2f6−/− mice with either
B16-OVA or MC38 tumor cells and monitored tumor growth.
Comparable to the Nr2f6−/− mice, tumor progression was also
significantly slower and overall tumor masses smaller in hetero-
zygous Nr2f6+/− mice (Fig. 4a, c). Heterozygous Nr2f6+/− mice
showed significant better survival after tumor challenge with both
B16 and MC38 cell lines similar to homozygous Nr2f6−/−mice
(Fig. 4b, d). Similarly, the treatment of MC38 tumor-bearing
heterozygous Nr2f6+/− mice with αPD-L1 is as effective as in
knockout mice (Fig. 4e). Infiltrate analyses of tumor-bearing
heterozygote animals also demonstrate enhanced numbers of
CD45+ cells. Haplo-insufficiency of the Nr2f6 gene function
in vivo is shown by the fact that one deficient allele of the Nr2f6
gene was sufficient to increase the immune system’s efficacy to
counteract tumor outgrowth. Investigation of cytokine and pro-
liferation responses of isolated CD4+ (Fig. 4f) and CD8+ (Fig. 4g)
T cells in vitro, albeit only in part, confirmed a functional effect of
haplo-insufficiency of the Nr2f6 gene.
Acute Nr2f6 inhibition is sufficient for hyper-responsiveness.
As previously reported, both murine CD3+ effector T cells (but
importantly not regulatory T cells23), activated in the absence of
NR2F6, exert enhanced effector functions. To confirm the
importance of NR2F6 as T-cell-intrinsic suppressor of T-cell-
mediated tumor growth control in vivo, we next employed ex vivo
siRNA-mediated Nr2f6 silencing prior ACT of autologous T cells
into a MC38 subcutaneous mouse tumor model. Fully immu-
nocompetent wild-type mice were injected with Nr2f6 siRNA or
siRNA control transfected polyclonal CD3+ T cells, in combi-
nation with PD-1/PD-L1 axis blockade, respectively. Adoptive
transfer of CD3Nr2f6 siRNA polyclonal T cells that demonstrated
significant Nr2f6 silencing (Fig. 5a) was sufficient for a significant
delay in tumor growth when compared to mice receiving
CD3control siRNA cells (Fig. 5b−d). Analysis of congenic marked
siRNA treated CD3control siRNA and CD3Nr2f6 siRNA T cells in a
competitive adoptive transfer experiment revealed significantly
elevated IL-2 levels in Nr2f6 siRNA transfected CD4+ T cells in
the draining lymph node of mice receiving PD-L1 blockade
therapy. In keeping with this finding, siRNA-mediated human
NR2F6 silencing induced hyper-responsiveness, as measured by
significantly augmented IFNγ and IL-2 responses, thus validating
an essential and non-redundant function of NR2F6 in human
T cells (Fig. 5e-j), a result highly reminiscent of the murine Nr2f6
knockout T cells ex vivo. Adoptively transferred Nr2f6 silenced
CD3+ T cells therefore act as robust “sensitizer” for the estab-
lished anti-PD-L1 immune checkpoint blockade in mouse tumor
models in vivo.
Of note, although the NR2F family consists of three orphan
receptors (designated as NR2F1, NR2F2 and NR2F6), only
NR2F2 and NR2F6 were found to be expressed in primary human
T cells (Supplementary Fig. 5A, B). Within the NR2F family,
NR2F6 has an isotype-selective role in immune cells as is shown
by strongly enhanced expression of NR2F6 (but not NR2F2) upon
CD3/CD28-induced human T-cell stimulation. Human NR2F6
mRNA expression levels increased after CD3/CD28 stimulation,
reaching levels of up to a fivefold (for CD4+ T cells) or up to a
tenfold (for CD8+ T cells) augmentation (Supplementary
Fig. 5A,B). Additionally, no compensatory upregulation of
NR2F2 mRNA as a consequence of NR2F6 siRNA-mediated
silencing was observed (Supplementary Fig. 5C, D). Finally, in
contrast to NR2F6, siRNA-mediated human NR2F2 silencing did
not induce any augmented IFNγ and IL-2 responses (Supple-
mentary Fig. 5E). Ex vivo siRNA-mediated Nr2f6 silencing and
stimulation of murine CD8+ T cells showed elevated IFNγ and
IL-2 responses measured by qRT-PCR (Supplementary Fig. 5F)
and FACS analysis (Supplementary Fig. 5G) detectable up to
7 days after transfection.
Taken together, siRNA-mediated Nr2f6 silencing as a single
negative regulator of T-cell signaling augments immune activity
Table 1 Immune-related adverse events (irAE) of MC38-tumor-bearing mouse treatment groups
Nr2f6+/+ IgG Nr2f6−/− IgG p value Nr2f6+/+ αPD-L1 Nr2f6−/− αPD-L1 p value
Colon length (cm) 10.3 ± 0.1 9.4 ± 0.4 0.066 9.4 ± 0.3 9.3 ± 0.3 0.82
Spleen weight (mg) 119 ± 15.2 110 ± 17.3 0.70 112 ± 4.6 119 ± 15.9 0.69
Spleen cellularity (×107) 5.9 ± 0.5 4.3 ± 0.7 0.11 5.0 ± 0.7 5.6 ± 0.7 0.56
Weight gain d90 (% BW) 19 ± 3.3 20.5 ± 6.5 0.89 22 ± 2 30 ± 5 0.42
CD3+ 29.7 ± 4.6 29.9 ± 4.4 0.98 29.9 ± 1.8 30.3 ± 4.1 0.94
CD3+CD69+ 12.3 ± 1.3 13.9 ± 2.7 0.62 9.5 ± 1.5 10.9 ± 1.2 0.52
CD4+ 24.2 ± 1.1 24.6 ± 0.5 0.77 22.6 ± 2.5 21.7 ± 1.4 0.77
CD4+CD62L+CD44+ 8.2 ± 0.7 6.4 ± 0.8 0.13 8.4 ± 0.6 7.6 ± 0.4 0.30
CD8+ 14.3 ± 1.3 12.6 ± 0.3 0.24 13.3 ± 1.7 11.4 ± 0.9 0.38
CD8+CD62L+CD44+ 16.9 ± 1.2 9.7 ± 0.7 0.13 18.7 ± 1.2 11.6 ± 0.1 0.003
B220+ 37 ± 5.5 46.3 ± 1.2 0.15 48.5 ± 1.3 47.5 ± 3.8 0.79
CD11b+ 9.5 ± 1.9 7.0 ± 0.6 0.27 8.8 ± 0.4 5.5 ± 0.6 0.003
CD11b+Ly6C+Ly6G+ 41.3 ± 3.1 39 ± 2.5 0.59 45.8 ± 3.9 39.2 ± 2.2 0.21
RBC (106/mm3) 11.5 ± 0.3 11.3 ± 0.1 0.72 12.2 ± 0.7 11.5 ± 0.6 0.47
WBC (103/mm3) 8.3 ± 0.3 12.3 ± 1.9 0.076 10.7 ± 1.2 8.2 ± 1.4 0.45
Hematocrit (%) 59.1 ± 3.2 55.3 ± 0.7 0.29 56.5 ± 1.9 58.7 ± 3.3 0.62
Lymphocytes (%) 75.5 ± 2.3 77.4 ± 2.0 0.56 75.6 ± 4.0 79.6 ± 3.4 0.49
Monocytes (%) 4.5 ± 0.4 4.5 ± 0.3 0.92 4.8 ± 0.7 4.3 ± 0.7 0.67
Granulocytes (%) 20.1 ± 1.9 18.1 ± 1.8 0.49 19.6 ± 3.2 16.1 ± 3.0 0.46
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in experimental mouse in vivo and human ex vivo model systems.
This defines a non-redundant role of NR2F6 as a negative
feedback loop during CD3+ effector T-cell activation.
Upregulation of NR2F6 in TILs from NSCLC tumor biopsies.
To establish a direct causal relationship between lympha-
tic NR2F6 and human cancer, intratumoral NR2F6 expression
was determined by immunohistochemical (IHC) analyses of tis-
sue microarrays (TMA). Importantly, NR2F6 protein expression
was seen in TILs. NR2F6 expression in TILs was upregulated in
more than 50% (164 of 303: 54%) of NSCLC patients (Fig. 6a).
When using a staining score from 0 to 4, lung cancer tissue clearly
contained higher numbers of NR2F6-expressing TILs when
compared to healthy lung tissue (Fig. 6b). Significant higher
NR2F6 mRNA expression could also be seen in sorted CD3+
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T cells of tumor tissue from NSCLC patients compared to PBMCs
(Fig. 6c). However, expression levels of NR2F6 in TILs were not
linked to overall survival in the examined patients. This also
includes the high (>3–4) NR2F6 expression group (Fig. 6d).
Notably, however, the number of NR2F6-expressing TILs was
highly correlated to the abundance of PD-1 and CTLA-4-
expressing TIL as well as PD-L1 expression on tumor cells
(Fig. 6e, Supplementary Fig. 6). These data suggest a potential
rationale for combined targeting of NR2F6 and PD-L1/PD-1 in
human cancer and may hint at a specific immunological finger-
print helping to select or stratify patients for the most appropriate
immune-activating therapeutic strategy.
Taken together, NR2F6 expression in TILs of NSCLC may be
linked to T-cell dysfunction/exhaustion phenotype that supports
its potential suitability as an additive or even synergistic target for
immune-activating strategies to be combined with established
checkpoint blockade.
Discussion
The challenge in the field of cancer immunology is to discover the
most suitable targets as well as their best combinations for
therapeutic intervention. In this study we provide evidence for an
essential and non-redundant role of NR2F6 in critically antag-
onizing anti-cancer effector T-cell responses. We made the
remarkable observation that loss of NR2F6 enhances the activity
of established PD-L1 checkpoint blockade to promote tumor
regression and increased survival in subcutaneous tumor models.
The synergistic therapy outcome indicates that NR2F6 blocking is
a mechanistically independent option and indicates that inhibi-
tory targeting of NR2F6 may provide novel immunotherapeutic
avenues to enhance T-cell checkpoint immunotherapy. Impor-
tantly, despite the dramatically improved clinical outcome in
Nr2f6−/− tumor-bearing mice, no exacerbated signs of irAE were
observed in the combinatorial NR2F6/PD-L1 targeting group
when directly compared to the mono-therapy mice, suggesting
that major side effects might not hamper the therapeutic potential
of this combinatorial approach.
Nuclear receptors are transcription factors that have been
shown to be essential for both pro- and anti-inflammatory T-cell
responses24,25. Of note, nuclear receptors generally regulate gene
expression in response to the binding of lipophilic ligands and
thus, the nuclear receptor family has a strong history of successful
drug discovery26–28. There is as yet no valid information about
endogenous ligands for several human nuclear receptors includ-
ing NR2F629,30. However, although the NR2F family members
are classified as orphan receptors, their ligand-binding domain
(LBD) is both evolutionarily conserved and functionally indis-
pensable for its transcriptional activity22,31. Mutations within the
LBD of NR2F6, reducing the size of the ligand-binding pocket or
disrupting co-repressor interactions, have shown to significantly
reduce its transcriptional repressor function22, indicating that
endogenous ligands for NR2F6 may exist and presumably mod-
ulate NR2F6 function.
Along this line of argumentation, intriguingly, even hetero-
zygous Nr2f6+/− mice exhibited the same ability to delay tumor
outgrowth of implanted B16-OVA and MC38 tumors as Nr2f6
knockout mice. Because complete Nr2f6 deficiency, as in homo-
zygous knockout mouse models, hardly represents the physiolo-
gical level of inhibition that can be reached during clinical
regimens, this observed haplo-insufficiency of the Nr2f6 gene
function in vivo further supports the suitability of NR2F6 as a
target for cancer immunotherapy. Thus, not only complete but
also partial (50%) NR2F6 deficiency, the latter representing a
fairly realistic scenario of therapeutic inhibition, is sufficient to
strengthen anti-tumor immunity. In agreement with these
observations, acute Nr2f6 gene silencing in both mouse and
human T cells induced hyper-responsiveness, firmly validating a
non-redundant T-cell inhibitory function of NR2F6.
Because T lymphocyte-intrinsic NR2F6 acts as a potent and
selective repressor of effective cancer immunity, NR2F6 appears
to represent a crucial regulator of cancer immune tolerance
induction and maintenance. Mechanistically, as examined by
RNA sequencing of TILs derived from tumor-bearing mice,
NR2F6 appears to set the threshold of T-cell effector functions as
transcriptional regulator of critical target genes shaping activa-
tion, recruitment, proliferation and homeostasis of tumor-
antigen-specific T-cell responses.
It has been shown that T cells in the TME frequently express
high levels of inhibitory receptors as a sign of T-cell exhaustion,
including PD-1, CTLA-4, as well as impaired effector cytokine
production, such as IL-2, TNFα, IFNγ. Interestingly, this
impairment of cytokine production would correlate with high
levels of NR2F6 expression, as IL-2, TNFα and IFNγ are direct
target genes of NR2F6-dependent transcriptional repression23.
Along this line of argumentation, a positive correlation between
NR2F6 expression and cancer has been reported; studies have
identified NR2F6 to be upregulated in human ovarian cancer,
colon cancer and lymphoma32–38. However, it is not possible
from these published data to determine whether the origin of
NR2F6 expression is the malignant or the immune cell. Notably,
in the tumor-infiltrating T cells of 54% of lung cancer patients,
NR2F6 upregulation has been observed within the TME. This
suggests that targeting the immune checkpoint NR2F6 in those
Fig. 3 Nr2f6 expression alters gene signature of tumor-reactive T cells. a Principal component analyses of the RNA-seq data from pre-sorted CD3+ tumor-
infiltrating T cells of Nr2f6+/+ IgG2b (n= 3), Nr2f6+/+ αPD-L1 (n= 5), Nr2f6−/− IgG2b (n= 3) and Nr2f6−/− αPD-L1- (n= 5) treated tumor-bearing mice
taken at d14 after tumor injection of 5×105 B16-OVA melanoma cells separates the TILs into four distinct clusters. b−d ClueGO analysis of up- and
downregulated genes in isolated TILs from combinatorial NR2F6/PD-L1 therapy groups. CD3+ TILs from either Nr2f6+/+ or Nr2f6−/− mice with PD-L1
blockade therapy were isolated, RNA-seq was performed and the significantly differentially expressed genes were subsequently analyzed using ClueGO.
The enriched gene ontology terms are shown as functionally grouped nodes in an interconnected network based on their score level. The sizes of the nodes
reflect the enrichment significance of the terms, while functionally related groups partially overlap. Terms with up-/downregulated genes are shown in
green/red, respectively. The color gradient shows the gene proportion of each group (up- or downregulated group of genes) associated with the term.
Equal proportions of the two groups are represented in gray. The pie charts show the enriched groups represented by the most significant term. The sizes
of the sections correlate with the number of terms included in a group. The key upregulated pathways (c) in TILs from Nr2f6−/− mice with PD-L1 blockade
are: cell-mediated cytotoxicity (p= 0.0001), IFNγ signaling (p= 0.0004), TCR signaling pathway (p= 0.0006), immune system function (p= 0.0009),
Wnt signaling pathway (p= 0.0029), type II IFN signaling (p= 0.0042), TNF signaling pathway (p= 0.0045). e GSEA enrichment plot of KEGG
endometrial cancer pathway genes of sorted CD3+ TILs from Nr2f6+/+ αPD-L1 versus Nr2f6−/− αPD-L1-treated tumor-bearing mice. Genes in the KEGG
endometrial cancer signaling pathway showed significant enrichment in T cells and CD4 Th1 signature (FDR q value=0.006). The top portion of the figure
plots the enrichment scores (ES) for each gene, whereas the bottom portion of the plot shows the value of the ranking metric moving down the list of
ranked genes. f Heat map showing most prominent deregulated genes: Nfatc1; Nfatc2; Klrc2; Cd48; Klra3; Ppp3cc; Klrd1; Socs3; Stat1; Camk2b; Cd28; Il10; Prkcq;
Adcy7; Hectd3; H2-DMa; Dapp1; Rps6kb2; Cybb; Ripk3; Tnfaip3; Prkacb; Zbp1; Junb; Ccl5
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presumably tumor antigen-reactive but probably exhausted T-cell
clones in the patient group with NR2F6positive TILs may result in
increased anti-tumor effector responses during an envisioned
NR2F6-targeted therapy.
According to all our preclinical data, high NR2F6 expression is
likely to critically contribute to the immune-suppressed state of
tumor antigen-specific TILs, thus limiting the host’s anti-tumor
immune response. Absence of NR2F6, either through genetic abla-
tion in Nr2f6 knockout mice or by the means of siRNA knock-
downs, increases the immune system’s ability to mount effective
immune responses, resulting in striking anti-tumor effects in dif-
ferent advanced mouse models relevant to human cancer.
This preclinical proof of concept study on the Nr2f6 gene
depletion-mediated immune augmentation is envisioned as a way
forward to extend the benefits of clinical immuno-oncology
therapies to a larger number of cancer patients. The unique fea-
ture of lymphatic NR2F6 as an alternative immune checkpoint
may influence cancer therapy in the future, both in terms of
targeting cancer pathways using small molecule inhibitors, and
individualized adoptive therapy of NR2F6 gene-modified human
T cells, a hypothesis that now requires further validation.
Methods
Mice. Nr2f6-deficient mice39 back-crossed eight times on C57BL/6 background
were used. Mice were maintained under SPF conditions. All animal experiments
were performed in accordance with national and European guidelines and reviewed
and authorized by the committee on animal experiments (BMWFW-66.011/0064-
WF/V/3b/2016). Investigations were strictly gender‐stratified and not blinded.
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Fig. 4 Heterozygous Nr2f6+/− mice similarly show strong tumor growth benefit. Tumor growth curves of Nr2f6+/+, Nr2f6+/− and Nr2f6−/− mice that
received a 1×105 B16-OVA melanoma cells (Nr2f6+/+ (n= 21), Nr2f6+/− (n= 11), and Nr2f6−/− (n= 21)) or c 5×104 MC38 tumor cells (Nr2f6+/+ (n=
16), Nr2f6+/− (n= 5), and Nr2f6−/− (n= 10)) subcutaneously and were monitored three times a week showing a significant tumor growth delay as well as
a survival benefit (b-d) in Nr2f6 gene-modulated mice (p<0.0001 for both tumor cell lines, ANOVA). e Tumor growth curves of Nr2f6+/+ (IgG2b n= 5,
αPD-L1 n= 10), Nr2f6−/− (IgG2b n= 7, αPD-L1 n= 12) and Nr2f6+/− (IgG2b n= 3, αPD-L1 n= 3) mice injected s.c. with 5×105 B16-OVA melanoma cells
and treated with PD-L1 blockade (continuous line) or IgG2b (dashed line) (n= 3–5). Both αPD-L1 treated Nr2f6+/− (p= 0.0179, ANOVA) and Nr2f6−/− (p
< 0.0001, ANOVA) showed a significant slower tumor growth when compared to treated wild-type controls. f, g In vitro flow cytometry analysis of isolated
CD4+ or CD8+ T cells activated with anti-CD3 mAb (5 µg) and anti-CD28 mAb (1 µg) at d3 from Nr2f6+/+, Nr2f6+/− or Nr2f6−/− mice (n= 3). Analysis
of IL-2 and IL-17-producing CD4+ Th0 and Th17 T cells, Ki67+ proliferating CD4+ and CD8+ T cells, and IFNγ as well as IL-2 production of CD8+ T cells.
Percentage of positive cells relative to parental gate is shown; experiments were repeated at least three times. Results shown are derived from at least two
independent experiments. Error bars represent the mean ± SEM
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Experimental mice were randomly chosen from litters with a minimal sample size
of three.
Tumor induction and adoptive cell transfer. 1×105 B16-OVA, 5×104 MC38
(kindly provided by Maximillian Waldner, University of Erlangen, Germany) were
injected subcutaneously (s.c.) into the left flank of 8- to 12-week-old wild-type,
Nr2f6+/− or Nr2f6−/− mice. For in vivo antibody blockade experiments, a higher
tumor load was used by s.c. injection of 5×105 B16-OVA or 7.5×105 MC38 tumor
cells. The high tumor load (5×105) was applied with therapy (anti-PD-L1 or ACTs)
to ensure robust tumor growth. Tumor growth was monitored three times a week
by measuring tumor length and width. Tumor volume was calculated according to
the following equation: ½(length × width2). For survival analysis, mice with tumors
greater than the length limit of 15 mm were sacrificed and counted as dead. Cell
lines were tested negative for mycoplasma (GATC, Konstanz, Germany).
In vivo antibody blockade. Mice were injected s.c. with 5×105 B16-OVA mela-
noma cells or 7.5×105 MC38 tumor cells and administered either 0.5 mg (B16-
OVA) or 0.25 mg (MC38) of anti-mouse PD-L1 (Clone10F.9G2; BE0101) or cor-
responding IgG2b (LTF-2; BE0090), control (all from BioXCell, USA) every 3 days
starting from day 1 or day 3 of tumor challenge according to ref.40. For CD4+ and
CD8+ depletion experiments, mice were administered 0.05 mg of anti-mouse CD4
(Clone GK1.5), anti-mouse CD8 (clone YTS169.4) or corresponding IgG2b (LTF-2;
BE0090) 5 days and 3 days before s.c. injection of 1×105 B16-OVA melanoma cells
as well as 5 and 12 days after tumor challenge.
MCA carcinogenesis model. Groups of female wild-type and Nr2f6−/− mice were
inoculated s.c. in the hind leg with 200 mg of 3-MCA (Sigma-Aldrich) in 0.1 ml of
corn oil as described41. Mice were then monitored weekly for fibrosarcoma
development over 300 days and recorded as percentage of tumor-free mice.
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Fig. 5 Nr2f6 gene silencing is effective and leads to hyper-responsiveness of T cells. a−d Tumor growth effects depend primarily on NR2F6 function in
CD3+ T cells. a Mouse Nr2f6 gene silencing is effective in CD3+ T cells (p= 0.002, unpaired t-test). Mouse CD3+ T cells were nucleofected with Nr2f6
siRNA or control siRNA as indicated. Silencing efficacy of Nr2f6 siRNA was analyzed by qRT-PCR and normalized to Gapdh (n= 3). b−d Wild-type
recipients received 5×105 MC38 tumor cells s.c. and were treated with therapeutic adoptive cell transfers (ACT) of 1×107 CD3+ T cells transfected with
control (black, n= 8) or Nr2f6 (green, n= 8) siRNA on d3 and d10 after tumor injection (p= 0.0172, ANOVA). Mice were also treated with 0.25mg of
antibody against PD-L1 (Ab10F.9G2) on the respective days. Single tumor growth curves of wild-type mice receiving ACT of c control siRNA transfected
CD3+ T cells or d Nr2f6 siRNA silenced CD3+ T cells. In the Nr2f6 siRNA ACT group, one mouse (11.1%) was able to reject the high tumor burden
completely, but all mice of the control siRNA ACT group had to be killed latest on d19. e−j Human CD4+ and CD8+ T cells were nucleofected with NR2F6
siRNA or control siRNA as indicated (n= 3). Silencing efficacy of Nr2f6 siRNA was analyzed by qRT-PCR (e CD4+ p= 0.0037, h CD8+ p= 0.002) and
immunoblotting (i) of CD8+ T cells. Cytokine production was measured by qRT-PCR after 5 h of PDBu (0.05 µg/ml)/ionomycin (0.5 µg/ml) stimulation
and showed significantly elevated levels of IL2 (p= 0.009) and IFNG (p= 0.04) in CD4+ T cells (f) as well as IL2 (p= 0.046) and IFNG (p= 0.05) in
CD8+ T cells (i). g Bioplex protein analysis also showed elevated levels of IFNγ (p= 0.019) and IL-2 (p= 0.017) in human CD4+ T cells transfected with
Nr2f6 siRNA. Similar results were obtained with non-overlapping Nr2f6 siRNA oligonucleotides. Results shown are derived from at least two independent
experiments. Data are presented as the mean ± SEM, analyzed by a two-tailed unpaired Student’s t-test
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Palpable tumors 10 mm2 with progressive growth for two successive weeks were
recorded.
3-MCA tumor-induced cell lines. Sarcomas that had reached a size of 0.5 cm2
were excised aseptically. Tumors were cut into small pieces and treated with 1 mg/
ml collagenase (type II; Sigma-Aldrich) and 40 µg/ml DNase I at 37 °C for 1 h,
clumps were removed, and single cells were cultured in RPMI 1640 complete
medium (10% FCS, 2 mM L-glutamine, and 50 U/ml penicillin/streptomycin). The
cells were split with Trypsin/EDTA (T3924 Sigma) when they were confluent. All
tumor cell lines were kept in culture for at least 2 months to minimize cellular
contamination. Some sarcoma lines were injected s.c. into wild-type or Nr2f6-
deficient mice as indicated.
Preparation of tumor-infiltrating cells. Mononuclear infiltrating cells were iso-
lated from both subcutaneous and chemically induced tumors at the indicated time
points. Briefly, tumor tissues from sacrificed mice were prepared by mechanical
disruption followed by digestion for 45 min with collagenase D (2.5 mg/ml; Roche,
11088858001) and DNase I (1 mg/ml; Roche, 11284932001) at 37 °C. Digested
tissues were incubated 5 min at 37 °C with EDTA (0.5 M) to prevent DC/T-cell
aggregates and mashed through a 100-µm filter and a 40-µm filter. Cells were
washed, and resuspended in either PBS+ 2% FCS or RPMI complete medium (10%
FCS, 2 mM L-glutamine, and 50 U/ml penicillin/streptomycin) and used for sub-
sequent experiments.
Flow cytometry. Splenocytes were depleted of erythrocytes using the mouse ery-
throcyte lysing kit (R&D, WL2000) and, like lymph node cells, mashed through a
100-µm filter. Splenocytes, lymph node cells and TILs were incubated with FcR
Block (BD Biosciences, 553142) to prevent nonspecific antibody binding before
staining with appropriate surface antibodies for 30 min at 4 °C, washed with PBS+
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Fig. 6 IHC and qRT-PCR analyses of NSCLC tumor biopsies show upregulation of NR2F6 in TILs that may serve as marker of patient stratification. a In
patient tumor biopsies, there is significantly upregulated expression of NR2F6 in T cells (marked by arrows) in 54% of the cases (163 of 303 patients). b
There is a significantly enhanced expression of NR2F6 in TILs from NSCLC tumor biopsies when compared to benign lung tissue (n= 303 and n= 10, p <
0.001). c Significant higher NR2F6 expression levels (p= 0.038, unpaired t-test) determined by qRT-PCR in CD3+ cells sorted from NSCLC tumor biopsies
when compared to PBMC samples. d The number of NR2F6-expressing TILs was defined as categorial variable: 0= 0%, 1= 1–25%, 2= 26–50%, 3=
51–75% and 4= 76–100% NR2F6-positive TILs. The number of NR2F6-expressing TILs is not linked to clinical outcome as seen in overall survival of
NSCLC patients from these defined staining categories (0–4). e Multiplex IHC analyses showed that the increase in lymphatic NR2F6 expression strongly
correlated with lymphatic PD-1 expression (Pearson correlation coefficient r= 0.553, p < 0.001). There was a positive correlation also between lymphatic
NR2F6 and lymphatic CTLA-4 (r= 0.145, p < 0.01) and tumor cell PD-L1 (r= 0.135, p < 0.01) expression, respectively
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2% FCS, and used for FACS analysis. For intracellular cytokine staining, cells were
stimulated with 50 ng/ml phorbol 12,13-dibutyrate (PDBu, Sigma, P1269), 500 ng
ionomycin (Sigma, I0634) and GolgiPlug (BD Biosciences, 555029) for 4–5 h. After
fixation (cytokines: Biolegend fixation buffer (420801), 20 min, 4 °C; transcription
factors: FoxP3 staining buffer set (eBiosciences, 00-5523), >30 min, 4 °C), cells were
permeabilized with the fixation/permeabilization kit (BioLegend, 421002) for
cytokines and the Foxp3-staining buffer set (eBiosciences, 00-5523) for transcrip-
tion factors, incubated with FcR Block (BD Biosciences, 553142) before staining
with specific cell surface or intracellular marker antibodies. Data were acquired on
an FACSCalibur, LSR Fortessa or FACS Verse cell analyzer (Becton Dickinson).
Data were analyzed using FlowJo software (version 10). The following antibodies
were used for flow cytometry: CD4-V500 (BD, 560783), CD4-PE (BD, 553049),
CD8a-APC (BD, 553035), CD25-PE (BD, 553866), CD44-FITC (BD, 553270),
CD62L-APC (BD, 553152), PD-1-PE (BD, 561788), Ki67-PE (BD, 556027), IL-17-
PE (BD, 559502), IL-2-APC (BD, 554429), CD45-V500 (BD, 561487), CD45-FITC
(eBiosciences, 11-0451-82), CD8a-PE (eBiosciences, 12-0081-82), CD8a-PerCP
Cy5.5 (eBiosciences, 45-0081-82), CD44-PerCP Cy5.5 (eBiosciences, 45-0441-82),
IFNƴ-PE-Cy7 (eBiosciences, 25-7311-82), PDL-1-PerCP-eFluor710 (eBiosciences,
46-5982-80), CD45-APC (eBiosciences, 17-0451-81), CD3-PE-Cy7 (eBiosciences,
25-0031,82), FoxP3-FITC (eBiosciences, 11-5773-82), CD3-PE (eBiosciences, 12-
0031-83), CD8a-bv421 (BioLegend, 100738), CD25-bv421 (BioLegend, 102034).
siRNA Nr2f6 inhibition in vitro. Isolated mouse or human T cells as described
above were used for transfection by the established method, namely siRNAs
employing Lonza® Nucleofection Technology using the human T-cell nucleofector
kit from Amaxa (Lonza, VPA-1002). Transfected mouse T cells were incubated in
complete RPMI medium supplemented with 2.5 ng/ml IL-7 (RnD, 407-ML), 2 ng/
ml IL-2 (eBiosciences, 14-8021-64) and 50 ng/ml IL-15 (Biolegend, 566302) for 48
h before further restimulation. The used siRNA sequences for mouse: siRNA J-
054088-11, Nr2f6, GCAUCGACAACGUGUGCGA, and human: siRNA J-003423-
06 NR2F6, CGGCAAGCAUUACGGUGUC (both from ThermoScientific).
siRNA Nr2f6 inhibition and adoptive cell transfer. 5×105 MC38 tumor cells were
injected s.c. into C57BL/6 wild-type recipients. Two adoptive cell transfers (ACT)
of control or Nr2f6 siRNA transfected CD3+ T cells into wild-type mice was per-
formed 3 and 10 days after tumor induction by injecting 1×107 sorted CD3+ T cells
using the Pan T Cell Isolation Kit II mouse (Miltenyi Biotech 130-095-130) via
intra-peritoneal injection. Ab treatment with 0.25 mg anti-mouse PD-L1 (Clo-
ne10F.9G2; BE0101) was administered i.p. on d3, d6, d10, d14, d17 and d21.Tumor
growth was subsequently measured as described above.
Immunohistochemistry. Protein expression in paraffin-embedded NSCLC tissue
was assessed on TMA from a cohort provided by the University Hospital Basel
containing 405 samples of NSCLC patients from which 303 samples were evalu-
able42,43. For TMA construction, formalin-fixed paraffin-embedded tissues were
cut in 4-µm-thick sections and mounted on slides. After staining with hematoxylin
and eosin, relevant areas of NSCLC were determined and circled by a pathologist.
Four representative cores of the circled regions measuring 0.6 mm in diameter
from each formalin-fixed paraffin-embedded NSCLC tissue (donor blocks) were
assembled into tissue microarray blocks (recipient blocks) using a semiautomatic
tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Immunohistochemical
(IHC) staining was performed using the Ventana Discovery automated staining
system (Ventana Medical System, Tuscon, AZ, USA). Slides were incubated at
room temperature with the following primary antibodies: anti-NR2F6 rabbit
polyclonal (1:100, ab137496, abcam, Cambridge, UK), anti-PD1 mouse mono-
clonal (1:100, ab52587, abcam, Cambridge, UK), anti-PD-L1 [28-8] rabbit
monoclonal (1:100, ab205921, abcam, Cambridge, UK), anti-CTLA-4 mouse
monoclonal (1:100, sc376016, Santa Cruz Biotechnology, Santa Cruz, CA), anti-
CD4 mouse monoclonal (1:50, 4B12, Leica Biosystems, Wetzlar, Germany) and
anti-CD8 mouse monoclonal (1:40, SP57, Leica Biosystems, Wetzlar, Germany).
Detection of the primary antibody was done with the ultraView Universal DAB
detection kit (Ventana Medical System, Tuscon, AZ, USA). NR2F6-, PD1, CTLA-4,
CD4- and CD8 expression in lymphocytes was assessed by two independent
pathologists. NR2F6 and CTLA-4 in lymphocytes were categorized in positive or
negative staining, and scored by numbers of positively stained TMA cores per
patient (score 0−4). PD-1, CD4, and CD8 were scored by numbers of positive-
stained lymphocytes per core (score 0−4 with 1= 1–25%, 2= 26–50%,
3= 51–75%, 4= 76–100%). PD-L1 staining intensity in tumor cells ranged from
0 to 3 (0= no staining, 1=weak staining, 2=moderate staining, 3= high stain-
ing), positive-stained cells were calculated as 0= no positive cells, 1= 1–25%,
2= 26–50%, 3= 51–75%, 4= 76–100%. PD-L1 was scored by immunoreactive
score (staining intensity × positive-stained cells).
Human whole blood samples. Human T cells were obtained from human per-
ipheral blood, which we get from the local blood bank. Informed consent from all
subjects was obtained by the Central Institute for Blood Transfusion at the Uni-
versity Hospital Innsbruck. Mononuclear cells were isolated from human periph-
eral blood by density centrifugation using Ficoll Buffer (VWR, 17-5442-02).
Magnetically sorted T cells (CD4: 130-045-101; CD8: 130-096-495, Miltenyi Kits)
were used for transfection or stimulation.
Human NSCLC samples. Five lung adenocarcinoma patients were analyzed for
their expression of NR2F6 on CD3+ TILs from single cell suspensions of primary
tumors and peripheral mononuclear cells. Approval by the regional ethical board
and written IC were given for all patients (AN 2014-0293342/4.5). Four out of five
patients were female, median age at diagnosis was 64 years (min 58; max 79). One
patient was diagnosed in pUICC stage IB, one in IIA, two IIB and one in stage IIIA.
All underwent radical surgical procedures in curative intent without prior
neoadjuvant therapies. Thawed cells from tumors and PBMC were stained with
antibodies against the following antigens: EpCam (FITC, Miltenyi 130-080-301);
CD45 (V450, BD Biosciences 560367); CD3 (BV480, BD Biosciences 566166), and
EpCam negative, CD45 and CD3 positive cells were sorted directly into RLT buffer
on a FACSAria I (BD Biosciences).
RNAseq at the i-med DeepSeq Core Facility. 5×105 B16-OVA tumor cells were
injected s.c. into wild-type or Nr2f6-deficient mice. Ab treatment with 0.5 mg anti-
mouse PD-L1 (Clone10F.9G2; BE0101) or control Ab IgG2b (LTF-2; BE0090) was
injected i.p. starting on d3 twice a week. On d14, tumors were harvested and
digested as described above. T cells of Nr2f6 wild-type and Nr2f6−/− mice were
pre-sorted with positive beads for CD4 (130-049-201) and CD8 (130-049-401)
T cells using kits from Miltenyi and pooled. Isolated T cells were stained with
fluorochrome-labeled antibodies recognizing mouse CD3 (17-0031-82,
eBioscience). To exclude dead cells, 12.5 µg/ml DAPI was added. Cells were sorted
on a BD FacsAriaTMIII Cell sorter (BD Biosciences) and directly collected in RLT
buffer (Qiagen) with RNAsin (N2515, Promega). RNA was isolated using the
RNeasy® Mini Kit (205113, Qiagen). RNA integrity was verified with the Agilent
Bioanalyzer. Ion TorrentTM compatible libraries were generated from 20 ng total
RNA input, using the QuantSeq 3′ mRNA-Seq Library Prep Kit from Lexogen
(Lexogen, Vienna Biocenter, Austria). Barcoded libraries were multiplexed and
sequenced on the Ion TorrentTM Proton Sequencer (Ion torrent, Thermo Fisher
Scientific). The Ion Torrent Suite was used for splitting of reads into barcodes, and
initial quality filtering and adapter trimming, resulting in a final output of an
average 28 million reads per sample. Data analysis has been performed blinded on
a collaborative basis with Prof. Trajanoski at the local institute for bionformatics
(http://icbi.i-med.ac.at/). The reads were first preprocessed through a high strin-
gency quality control pipeline consisting of adapter removal with Cutadapt44 and
quality trimming with Trimmomatic45 to remove bases with bad quality scores. All
reads shorter than 22 nucleotides were removed. The quality-trimmed reads were
then mapped to the mm10 reference genome using a two-step alignment method;
alignment with STAR46 followed by alignment of the unmapped reads with
Bowtie2. From the reads that mapped to multiple locations in the genome, only the
primary alignment was retained. Gene-specific read counts were calculated using
HTSeq-count. Differential expression analyses were performed using the R package
DESeq247. The p-values were adjusted for multiple testing based on false discovery
rate (FDR) using the Benjamini−Hochberg approach. Analysis and visualization of
Gene Ontology terms associated with differentially expressed genes was performed
using ClueGO48. Both groups of genes (up and downregulated, p-value <0.05) were
used as dual input for GO analysis. The biological terms are grouped together
based on their shared genes where the similarity between terms is calculated using
kappa statistics. The most significant term was chosen as a representative of the
group (Benjamini−Hochberg correction). Gene set enrichment analysis (GSEA)49
was used to identify immune cell types that are overrepresented in a phenotype.
Genes were ranked based on the log2FoldChange and used as an input to pre-
ranked GSEA together with a collection of metagenes that correspond to distinct
tumor-infiltrating leukocyte subtypes50.
Ex vivo T-cell analysis. CD8+ or CD4+ T cells were isolated using either the
mouse CD8 or CD4 T Cell Isolation Kit II or the human CD8 or CD4 T Cell
Isolation Kit (Miltenyi Biotec). CD8+ or CD4+ T cells were activated in complete
RPMI medium in the presence of plate-bound 2C11 for mouse or Okt3 for human
(αCD3, 5 μg/ml) and soluble mouse or human αCD28 (1 μg/ml). Naïve mouse
CD4+ T cells were isolated using the CD4+ CD62L+ T cell isolation kit II (Mil-
tenyi). Polarization of these CD4+ T cells into Th17 cells was performed in
complete IMDM medium supplemented with TGFβ (5 ng/ml), IL-6 (20 ng/ml),
IL-23 (10 ng/ml), anti-IFNγ, and anti-IL-4 (2 μg/ml). Cells were harvested at the
indicated time points.
Gene expression analysis. Total RNA was isolated using the RNeasy® Mini Kit
(Qiagen). First-strand cDNA synthesis was performed using oligo(dT) primers
(Promega) with the Qiagen Omniscript RT kit, according to the instructions of the
supplier and as described previously22. Expression analysis was performed using
real-time PCR with an ABI PRIM 7000 or ABI PRIM 7500fast Sequence Detection
System with TaqMan gene expression assays (Applied Biosystems); all mouse
expression patterns were normalized to Gapdh; all human expression patterns were
normalized to GAPDH or EEF1A2.
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irAE method. 1×104 MC38 (purchased from the ATCC) were injected sub-
cutaneously (s.c.) into the left flank of 8-week-old female wild-type or Nr2f6−/−
mice. In vivo antibody blockade was utilized administering 0.25 mg of anti-
mouse PD-L1 (Clone10F.9G2; BE0101) or corresponding IgG2b (LTF-2;
BE0090) i.p. twice a week in the first month, and once a week in the following
two months. Tumor growth was monitored one to three times a week by
measuring tumor length and width. Weight was measured every 2 weeks and
small blood samples were taken three times (beginning, middle and end of
experiment) for whole blood count analysis using a Vet abc classic hematology
system.
Western blotting. Cells were washed, and lysed in lysis buffer. Whole-cell
extracts or nuclear extracts were electrophoresed on NuPAGE gels (Invitrogen)
and transferred to PVDF membranes. Protein lysates were subjected to immu-
noblotting with antibodies against NR2F6 (FisherScientific Inc., USA: Pro-
teintech 2H2B8, 60117-2, 1:1000), and Actin (Santa Cruz Biotechnology Inc.,
USA: sc-1615, 1:1000). The uncropped scans are shown in supplementary
information (Supplementary Fig. 7).
Extracellular acidification assay. CD3+ T cells were stimulated with anti-CD3/
anti-CD28 for 3 days in RPMI medium and maintained in a CO2-free incubator
at 37 °C for 3 h prior to measurement. Growth medium was removed and cells
were washed with respiration buffer. 150 µl of respiration buffer containing pH
probe was added. Reagents were preheated to measurement temperature prior to
use. All plates were measured kinetically on a multilabel plate reader (PHER-
Astar, BMG Labtech) at 37 °C for a minimum of 30 min in time-resolved
fluorescence (TR-F) mode using a standard Europium filter set (340 ± 50 nm
excitation and 615 ± 8.5 nm emission). Two TR-F intensity signals were mea-
sured at delay times of 100 and 300 µs and a measurement window of 30 µs.
Using Microsoft Excel, these readings were converted to lifetime value s= (t1–
t2)/ln(D1/D2), where s is lifetime, t is delay time, and D is intensity values. ECA
was assessed as the rate of increase of probe signal (reflecting a decrease in [H
+]). OA (Oxamic acid, 1 µM) was used as a negative control. The MitoXpress®—
pH Xtra™ Glycolysis Assay Kit from Luxcel (Cat No. PH-100) was used.
Statistics. Data were analyzed using Prism 5.03 software (GraphPad Software).
Experiments were repeated at least two times with a minimum sample size (n) of
three. Data are represented as indicated (either the mean ± SEM or ±SD) for all
figure panels in which error bars are shown. Overall survival was expressed using
the Kaplan−Meier method, and differences between groups were determined using
the log-rank test. The p-values were assessed using two-tailed unpaired Student’s t-
test, or two-way ANOVA. A p value of <0.05 was considered statistically sig-
nificant. *p < 0.05; **p < 0.01; ***p < 0.001.
Data availability. The RNAseq data have been deposited in GEO under the
accession number GSE111796 The authors declare that all the other data sup-
porting the findings of this study are available within the article and its
Supplementary Information files and from the corresponding authors upon
reasonable request.
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